Clinical trial
Rituximab, Fludarabine, Cyclophosphamide, and Yttrium Y 90 Ibritumomab Tiuxetan…
NCT00397800 · Technical University of Munich, Other · Unknown status
Key facts
| NCT number | NCT00397800 |
|---|---|
| Title | Rituximab, Fludarabine, Cyclophosphamide, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Relapsed B-Cell Non-Hodgkin's Lymphoma |
| Official title | Safety and Efficacy of Sequential Treatment With a Combination of Rituximab, Fludarabine and Cyclophosphamide Followed by Zevalin (Rituximab and Y-Ibritumomab Tiuxetan) - A Phase I/II Study for Treatment of Patients With Relapsed Indolent and Transformed CD20-Positive B-Cell Non-Hodgkin's-Lymphoma… |
| Lead sponsor | Technical University of Munich, Other |
| Status | Unknown status |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Lymphoma |
| Intervention type | Biological, Drug, Radiation |
| Interventions | rituximab, cyclophosphamide, fludarabine phosphate, yttrium Y 90 ibritumomab tiuxetan |
| Enrollment | 12 |
| Start date | Jun 1, 2005 |
| Primary completion | May 1, 2008 |
| Completion | May 1, 2013 |
| First posted | Nov 10, 2006 |
| Last update posted | Aug 28, 2012 |
| Countries | Germany |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: